艾德生物：本次计提资产减值准备共计2683.02万元

Group 1 - Company Aide Biological (艾德生物) announced a provision for asset impairment totaling 26.83 million yuan, which will reduce the company's total profit for the first three quarters of 2025 by the same amount [1] - The asset impairment provision is unaudited and will be finalized based on the financial data audited by the accounting firm [1] - In 2024, Aide Biological's revenue composition is entirely from the in vitro diagnostic industry, accounting for 100% [1] Group 2 - As of the report date, Aide Biological has a market capitalization of 9.1 billion yuan [2] - The Chinese innovative drug sector has seen overseas licensing sales reach 80 billion US dollars this year [2] - There is a contrast in the biopharmaceutical secondary market being active while the primary market is experiencing a fundraising slowdown [2]